


OMTN, Volume 25

Supplemental information

Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA

Yoann Aldon, Paul F. McKay, Jorge Moreno Herrero, Annette B. Vogel, Réka Lévai, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Heinrich Haas, Katalin Fábíán, Roger Le Grand, Ugur Sahin, and Robin J. Shattock



Supplementary Figure 1. Comparison of VEEV- and SFV-based saRNA. Related to Figure 2. Groups of $n = 5$ BALB/c mice were immunized 3 times 3 weeks apart with escalating doses of polymer formulated (PLX) VEEV-based saRNA encoding the ConSOSL.UFO.664 gp140 protein (PLX A.I.R./VEEV-gp140) and compared to a SFV-based saRNA platform (PLX A.I.R./SFV-gp140). A PLX A.I.R./SFV-H1N1/Cf7-HA was included as a positive control group. **(A)** Antigen-specific IgG1 and **(B)** IgG2a titers as determined by ELISA. **(C)** The antigen-specific vaginal IgG was determined by ELISA. For **(A)**, **(B)** and **(C)**, box and whiskers with median, min-max and 25th-75th percentile. For **(A)** and **(B)**, the indicated p values compare VEEV to SFV for each week and each specific RNA dose. In **(C)**, p values indicated by arrows compare VEEV to SFV for each week and each specific RNA dose. Mann-Whitney unpaired t-test, p values: $* < 0.05$, $** < 0.01$ and $\alpha\alpha < 0.01$. ns, non-significant.